NCT07139171 Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia
| NCT ID | NCT07139171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Anding Hospital |
| Condition | Schizophrenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-11-11 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-11-11 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Schizophrenia is a severe mental illness characterised by positive symptoms, negative symptoms, and cognitive symptoms. In recent years, an increasing number of doctors and scholars have focused on cognitive symptoms; however, the mechanisms underlying cognitive impairment remain unclear. Recently, exosome research methods have provided new avenues for investigation. This study applies exosome research methods to first-episode, drug-naive schizophrenia patients to explore gene expression changes associated with cognitive impairment and gain a deeper understanding of the mechanisms underlying cognitive impairment. By integrating basic research with clinical findings, we aim to further investigate the molecular mechanisms underlying cognitive impairment in schizophrenia patients, identify potential intervention targets, and provide insights for future drug development.
Eligibility Criteria
Inclusion Criteria: * Healthy volunteers matched to the patient group on sex, age, and education level; * No family history of psychiatric disorders among first- or second-degree relatives (two generations); * Ethnic Han Chinese; * Able and willing to provide written informed consent. Exclusion Criteria: * Any serious physical illness, including but not limited to uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary, thyroid, or metabolic disease, diabetes, epilepsy, or metabolic syndrome; * Current or past diagnosis of substance-induced psychotic disorder, delusional disorder, brief psychotic disorder, or mood disorder with psychotic features; * Pregnancy or breastfeeding; * Any condition that would interfere with the ability to give informed consent or complete study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07139171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07139171 currently recruiting?
Yes, NCT07139171 is actively recruiting participants. Contact the research team at jieli@tjmhc.com for enrollment information.
Where is the NCT07139171 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07139171 clinical trial?
NCT07139171 is sponsored by Tianjin Anding Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.